{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:37:57Z","timestamp":1788255477341,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:p>The acute treatment of migraine requires matching patient need to drug and formulation. In particular, nausea and vomiting, quick time to peak intensity, and the common gastroparesis of migraineurs, all call for a variety of non\u2010oral formulations for treatment of attacks. A novel breath\u2010powered powder sumatriptan intranasal treatment offers an improvement, at least in pharmacokinetics, over conventional liquid nasal sumatriptan spray.<\/jats:p>\n                  <jats:p>The device for delivery in this breath\u2010powered nasal sumatriptan uses natural nose anatomy to close the soft palate and propel the sumatriptan high up in the nasal cavity on one side with bidirectional airflow coming out the other side. This approach has the potential to reduce adverse events and improve efficacy. Phase 3 data on this system are in press at the time of this writing and results appear promising.<\/jats:p>\n                  <jats:p>The clinical role for a fast acting non\u2010oral nasal formulation will be in those for whom tablets are bound to fail, that is, in the setting of nausea and vomiting or when the time to central sensitization, allodynia, and disabling migraine is too short for the patient to respond to a tablet. This review provides a clinical perspective on the breath\u2010powered powder sumatriptan intranasal treatment.<\/jats:p>","DOI":"10.1111\/head.12166","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T17:10:55Z","timestamp":1372439455000},"page":"1341-1349","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Implications for Breath\u2010Powered Powder Sumatriptan Intranasal Treatment"],"prefix":"10.1111","volume":"53","author":[{"given":"Stewart J.","family":"Tepper","sequence":"first","affiliation":[{"name":"Cleveland Clinic Headache Center  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00311.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2012.02741.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02292.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.770748"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2273.2004.00797.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.1998.1805241-4.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-0987(97)00073-0"},{"key":"e_1_2_8_9_1","article-title":"Breath powered nasal delivery of sumatriptan powder: A randomized, open\u2010label, crossover comparison of bioavailability and pharmacokinetics with a sumatriptan liquid nasal spray, tablet and subcutaneous injection in healthy subjects","volume":"53","author":"Obaidi M","year":"2013","journal-title":"Headache"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102409359314"},{"key":"e_1_2_8_11_1","article-title":"The TARGET study: A randomized, double\u2010blind, placebo\u2010controlled evaluation of breath powered nasal delivery of sumatriptan powder in the treatment of acute migraine","volume":"53","author":"Cady RK","year":"2013","journal-title":"Headache"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.5.1225"},{"issue":"8","key":"e_1_2_8_13_1","first-page":"S10","article-title":"Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: Results of a multicenter study","volume":"45","author":"Sargent J","year":"1995","journal-title":"Neurology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000099531"},{"key":"e_1_2_8_15_1","first-page":"809","article-title":"Rozen T for the CH\u20102004\u201003 Investigators. Abortive treatment of migraine headache with non\u2010inhaled, intranasal carbon dioxide: A randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study","volume":"45","author":"Spierings ELH","year":"2005","journal-title":"Headache"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00850.x"},{"key":"e_1_2_8_17_1","unstructured":"Available at:http:\/\/www.merck.com\/product\/usa\/pi_circulars\/m\/maxalt\/maxalt_pi.pdf(accessed February 23 2013)."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.111006257.x"},{"key":"e_1_2_8_19_1","unstructured":"Available at:http:\/\/us.gsk.com\/products\/assets\/us_imitrex_tablets.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_20_1","unstructured":"Available at:http:\/\/us.gsk.com\/products\/assets\/us_imitrex_injection.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_21_1","unstructured":"Available at:http:\/\/us.gsk.com\/products\/assets\/us_imitrex_nasal_spray.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_22_1","unstructured":"Available at:http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=621(accessed March 2 2013)."},{"key":"e_1_2_8_23_1","unstructured":"Available at:http:\/\/www.endo.com\/File%20Library\/Products\/Prescribing%20Information\/FROVA_Full_Prescribing_Information.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_24_1","unstructured":"Available at:http:\/\/us.gsk.com\/products\/assets\/us_treximet.pdf(accessed March 3 2013)."},{"key":"e_1_2_8_25_1","unstructured":"Available at:http:\/\/www.axert.com\/sites\/default\/files\/pdf\/prescribing\u2010information.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_26_1","unstructured":"Available at:http:\/\/us.gsk.com\/products\/assets\/us_amerge.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_27_1","unstructured":"Available at:http:\/\/www1.astrazeneca\u2010us.com\/pi\/zomignasalspray.pdf(accessed March 2 2013)."},{"key":"e_1_2_8_28_1","unstructured":"Available at:http:\/\/www1.astrazeneca\u2010us.com\/pi\/Zomig.pdf(accessed March 2 2013)."}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhead.12166","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.12166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:57:16Z","timestamp":1762073836000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.12166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/head.12166"],"URL":"https:\/\/doi.org\/10.1111\/head.12166","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]}}}